Octagon Capital Advisors’s Pharvaris PHVS Stock Holding History

Octagon Capital Advisors’s Portfolio PHVS Stock Details PHVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.66M	Sell	165,000 -506,465	-75%	-$13.5M	0.52%	26
2025 Q4	$18.6M	Sell	671,465 -51,130	-7%	-$1.23M	2.26%	19
2025 Q3	$18M	Buy	722,595 +50,000	+7%	+$1.11M	2.73%	15
2025 Q2	$11.8M	Sell	672,595 -97,220	-13%	-$1.57M	2.6%	18
2025 Q1	$12.1M	Sell	769,815 -8,185	-1%	-$138K	2.34%	17
2024 Q4	$14.9M	Buy	778,000 +157,530	+25%	+$3.24M	2.45%	17
2024 Q3	$11.5M	Buy	+620,470	New	+$11.3M	1.79%	17

Other funds holding PHVS

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

EFM

EQT Fund Management Luxembourg $1.02B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Octagon Capital Advisors's PHVS Position: Q1 2026 in Review

Octagon Capital Advisors reduced its Pharvaris (PHVS) stake by 75% in Q1 2026, selling an estimated $13.5M and leaving 165,000 shares worth $4.66M. The position accounts for 0.52% of the portfolio, ranked #26.

Octagon Capital Advisors first reported a position in PHVS in Q3 2024 and has held it in 7 quarters since. The position peaked at $18.6M in Q4 2025. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

Octagon Capital Advisors held 165,000 shares of Pharvaris worth $4.66M as of Q1 2026.
Octagon Capital Advisors sold 506,465 Pharvaris shares in Q1 2026, an estimated $13.5M.
Pharvaris made up 0.52% of Octagon Capital Advisors's portfolio in Q1 2026, its #26 holding.
Octagon Capital Advisors first reported a position in Pharvaris in Q3 2024 and has held it in 7 quarters since.
Octagon Capital Advisors's Pharvaris position peaked at $18.6M in Q4 2025.
110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.